FDA Approves ZOLL’s Zenix Monitor/Defibrillator

Asahi Kasei has advanced its suite of critical care products with U.S. Food and Drug Administration (FDA) premarket approval for ZOLL’s Zenix monitor/defibrillator, a device shaped by years of user feedback that reportedly is ZOLL’s most clinically advanced, user-friendly professional monitor/defibrillator.

Designed for use in EMS and hospital settings, the product features a large, durable touchscreen and functionality to automate workflows. Users can dynamically customize the device with real-time adjustments that make it easy to use in critical moments. The device also features ZOLL’s Real BVM Help and exclusive Real CPR Help technology.

ZOLL has been a major source of growth for Asahi Kasei’s Healthcare sector, driving a fivefold increase in net sales and a sevenfold rise in operating income since the company joined the Asahi Kasei Group in 2012. In its medium-term management plan, Asahi Kasei has indicated it will capitalize on this steady growth by introducing new products while maintaining market competitiveness.

“The approval of Zenix reflects our strategic, long-term focus on growth through high-value, solution-based technologies. This device has been designed with an understanding of customer needs, and we expect it will be well-received by customers and healthcare professionals,” commented Ken Shinomiya, Healthcare Sector leader at Asahi Kasei. “This innovation expands our critical care portfolio and offers healthcare providers an excellent tool to tackle their key challenges. We will stay competitive and reinforce our commitment to long-term profitable growth through these innovations.”

The Zenix monitor/defibrillator currently is available to U.S. and Canadian customers.

An Asahi Kasei company, ZOLL develops and markets medical devices and software solutions that help advance emergency care while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides technologies to help clinicians, EMS and fire professionals, and lay rescuers improve patient outcomes in critical cardiopulmonary conditions.

Since its foundation in 1922 with ammonia and cellulose fiber business, the Asahi Kasei Group has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 50,000 employees worldwide, the company contributes to sustainable society by providing solutions to the world’s challenges through Healthcare, Homes, and Material.